12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CG400549: Phase II start

This month, CrystalGenomics will begin an open-label, U.S. Phase II trial to evaluate once-daily CG400549 for 10-14 days in patients...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >